Allena Pharmaceuticals, Inc.

76 articles with Allena Pharmaceuticals, Inc.

• Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  7/14/2021

  Allena Pharmaceuticals, Inc. announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company’s common stock and warrants to purchase up to an aggregate of 10,678,872 shares of the Company’s common stock, at a purchase price of $1.311 per share of common stock and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules.

• Allena Pharmaceuticals Provides Update on Clinical Development Programs

  7/12/2021

  Allena Pharmaceuticals, Inc. provided progress updates on its clinical programs: ALLN-346, a first-in-class, oral urate degrading enzyme in development for the treatment of patients with hyperuricemia and gout in the setting of chronic kidney disease and reloxaliase, a first-in-class, oral oxalate degrading enzyme in development for the treatment of patients with enteric hyperoxaluria.

• Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

  7/8/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference.

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021

  7/7/2021

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of inducement awards to two new employees.

• Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney DiseaseWebinar Scheduled for Wednesday, June 16th @ 12 pm EDT

  6/8/2021

  Allena Pharmaceuticals today announced that it will host a key opinion leader (KOL) webinar on Wednesday, June 16, 2021 at 12:00 pm Eastern Daylight Time.

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 08, 2021

  6/8/2021

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of an inducement award to a new employee.

• Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

  5/11/2021

  Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 04, 2021

  5/4/2021

  Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the granting of an inducement award to a new employee.

• Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  4/8/2021

  Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to four new employees.

• Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

  4/7/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.

• Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  3/9/2021

  -- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyperuricemia and gout -- -- Management team strengthened with addition of David Clark, M.D., M.R.C.P as Chief Medical Officer and Richard Katz, M.D. as Chief Financial Officer -- NEWTON, Mass., March 09, 2021

• Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

  2/24/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March: Cowen’s 41 st Annual Health Care Conference

• Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --

  2/2/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO), effective immediately

• Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

  1/4/2021

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January:

• 

  Clinical Catch-Up: November 30-December 4

  12/7/2020

  It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.

• Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

  12/2/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares

• Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer

  12/1/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of David J. Clark, M.D., M.R.C.P, as Chief Medical Officer, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an

• Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

  12/1/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC

• Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346

  11/30/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers

• Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

  11/24/2020

  Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference